Influenza virus-mediated suppression of bronchial Chitinase-3-like 1 secretion promotes secondary pneumococcal

Diana Karwelat1, Bernd Schmeck1,2,3,4, Marc Ringel5

  • 1Institute for Lung Research, Universities of Giessen and Marburg Lung Center, Member of the German Center for Lung Research (DZL), Marburg, Philipps University Marburg, Hesse, Germany.

Insights

Influenza A virus infection reduces levels of Chitinase-3-like 1 (CHI3L1) in lung cells, promoting secondary bacterial infections. Restoring CHI3L1 levels combats this, offering a potential therapy for post-influenza bacterial pneumonia.

Area of Science:

  • Pulmonary Medicine
  • Infectious Diseases
  • Molecular Biology

Background:

  • Lung infections cause significant global mortality.
  • Secondary bacterial infections, especially after influenza A virus (IAV), worsen outcomes.
  • The role of Chitinase-3-like 1 (CHI3L1) in IAV and Streptococcus pneumoniae co-infection is unclear.

Purpose of the Study:

  • To investigate if IAV preinfection reduces CHI3L1 levels, promoting pneumococcal infection.
  • To elucidate the molecular mechanisms underlying severe IAV-S. pneumoniae co-infections.

Main Methods:

  • Utilized an air-liquid interface model of primary human bronchial epithelial cells (hBECs).
  • Employed confocal time-lapse microscopy to observe cellular changes and bacterial replication.
  • Assessed the effect of recombinant CHI3L1 on bacterial load in IAV-preinfected models.

Main Results:

  • IAV preinfection impaired apical release of CHI3L1 in hBECs.
  • Co-infection led to loss of apical CHI3L1, goblet, and ciliated cells, with increased S. pneumoniae replication.
  • Restoring CHI3L1 levels with recombinant protein significantly reduced bacterial load.

Conclusions:

  • IAV infection disrupts CHI3L1 localization, facilitating secondary bacterial growth.
  • CHI3L1 plays a protective role against S. pneumoniae in the context of IAV infection.
  • Recombinant CHI3L1 shows therapeutic potential for post-influenza bacterial pneumonia.

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
2.1K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.1K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.9K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
664
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
572